Stocktoria
Context Therapeutics Inc. CNTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-10-20
Context Therapeutics Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M | -$2.6M |
| Interest expense | — | — | — | — | $64,240 | $661,224 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M | $6.6M |
| EPS (diluted) | $-0.38 | $-0.46 | $-1.50 | $-0.93 | $-3.69 | $-3.96 |
| Operating cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.5M | -$8.8M | -$1.0M |
| Free cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.6M | -$8.8M | — |
| Cash & equivalents | $66.0M | $94.4M | $14.4M | $35.5M | $49.6M | $290,670 |
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M | $467,340 |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M | $9.6M |
| Shareholders' equity | $60.5M | $95.3M | $11.9M | $34.8M | $48.3M | -$16.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net income growth | — | — | — | — | -257.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.